Basilea. com : Basilea We are committed to developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with severe and life-threatening bacterial and fungal infections Basilea is located in the Basel area, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN)
Who we are : Basilea Basilea at a glance Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland Basilea has about 190 employees We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections
News : Basilea Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam Read more Download previous
What we do : Basilea Basilea has established several license and distribution agreements for isavuconazole covering well over 100 countries The partners include Astellas Pharma Inc for the U S and Pfizer for most of Europe (excluding the Nordic countries, where Unimedic is our distribution partner), Russia, Turkey, Israel, China and further countries in Asia
Careers : Basilea Basilea has once again been named among the 150 most innovative companies in Switzerland with rank 29, an achievement that reflects our hard work, creativity, and dedication
Investor center : Basilea At Basilea, we have performed a materiality analysis in 2023 that helped us to understand, which environmental, social, governance (ESG) and economic topics matter most in the context of Basilea’s business model
News : Basilea Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has initiated the Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis (FAST-IC) phase 3 study
News : Basilea Basilea gibt die folgende Guidance für das Gesamtjahr (GJ) 2025: Für den Gesamtumsatz wird ein Anstieg um 8 % auf CHF 225 Mio erwartet Basilea kann die Auswirkungen der Aufwertung des Schweizer Frankens und der zuvor angekündigten Verringerung der Produktlieferungen an Pfizer auf die Cresemba- und Zevtera-basierten Umsätze ausgleichen
Calendario